Incyte Corporation (0J9P.L)
USD 69.2
(0.13%)
USD 69.2
(0.13%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 38.28 Million USD | -14.22% |
| 2022 | 44.63 Million USD | 30.26% |
| 2021 | 34.26 Million USD | -1.69% |
| 2020 | 34.85 Million USD | -31.49% |
| 2019 | 50.88 Million USD | 191.85% |
| 2018 | 17.43 Million USD | -27.36% |
| 2017 | 24 Million USD | -96.32% |
| 2016 | 651.48 Million USD | 5.1% |
| 2015 | 619.89 Million USD | -10.05% |
| 2014 | 689.11 Million USD | 4.16% |
| 2013 | 661.56 Million USD | 99.82% |
| 2012 | 331.07 Million USD | 4.72% |
| 2011 | 316.15 Million USD | 7.74% |
| 2010 | 293.43 Million USD | -33.78% |
| 2009 | 443.13 Million USD | 11.86% |
| 2008 | 396.16 Million USD | 2.49% |
| 2007 | 386.55 Million USD | 4.16% |
| 2006 | 371.1 Million USD | 8.55% |
| 2005 | 341.86 Million USD | -9.74% |
| 2004 | 378.76 Million USD | 125.74% |
| 2003 | 167.78 Million USD | -2.47% |
| 2002 | 172.03 Million USD | -4.02% |
| 2001 | 179.24 Million USD | -4.56% |
| 2000 | 187.81 Million USD | 93807.0% |
| 1999 | 200 Thousand USD | -75.0% |
| 1998 | 800 Thousand USD | -33.33% |
| 1997 | 1.2 Million USD | 1100.0% |
| 1996 | 100 Thousand USD | 0.0% |
| 1995 | 100 Thousand USD | -50.0% |
| 1994 | 200 Thousand USD | -75.0% |
| 1993 | 800 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 37.39 Million USD | -2.33% |
| 2024 Q3 | 32.15 Million USD | -2.77% |
| 2024 Q2 | 37.54 Million USD | 0.41% |
| 2023 Q3 | 31.92 Million USD | -19.67% |
| 2023 Q2 | 39.74 Million USD | 20.98% |
| 2023 Q1 | 32.84 Million USD | -26.41% |
| 2023 FY | 38.28 Million USD | -14.22% |
| 2023 Q4 | 38.28 Million USD | 19.94% |
| 2022 Q2 | 46.59 Million USD | -0.6% |
| 2022 Q1 | 46.88 Million USD | 36.81% |
| 2022 FY | 44.63 Million USD | 30.26% |
| 2022 Q4 | 44.63 Million USD | 6.07% |
| 2022 Q3 | 42.08 Million USD | -9.7% |
| 2021 Q3 | 43.62 Million USD | -3.57% |
| 2021 Q4 | 34.26 Million USD | -21.45% |
| 2021 FY | 34.26 Million USD | -1.69% |
| 2021 Q1 | 34.47 Million USD | -1.11% |
| 2021 Q2 | 45.24 Million USD | 31.24% |
| 2020 FY | 34.85 Million USD | -31.49% |
| 2020 Q1 | 60.41 Million USD | 18.73% |
| 2020 Q2 | 61.75 Million USD | 2.22% |
| 2020 Q3 | 57.43 Million USD | -6.99% |
| 2020 Q4 | 34.85 Million USD | -39.31% |
| 2019 Q3 | 18.08 Million USD | -64.05% |
| 2019 Q4 | 50.88 Million USD | 181.43% |
| 2019 FY | 50.88 Million USD | 191.85% |
| 2019 Q1 | 17.64 Million USD | 1.22% |
| 2019 Q2 | 50.29 Million USD | 185.01% |
| 2018 Q4 | 17.43 Million USD | -29.91% |
| 2018 FY | 17.43 Million USD | -27.36% |
| 2018 Q1 | 24.27 Million USD | 1.12% |
| 2018 Q2 | 24.57 Million USD | 1.23% |
| 2018 Q3 | 24.87 Million USD | 1.23% |
| 2017 Q1 | 41.6 Million USD | -93.61% |
| 2017 FY | 24 Million USD | -96.32% |
| 2017 Q4 | 24 Million USD | 1.22% |
| 2017 Q3 | 23.71 Million USD | 1.21% |
| 2017 Q2 | 23.42 Million USD | -43.69% |
| 2016 FY | 651.48 Million USD | 5.1% |
| 2016 Q1 | 627.64 Million USD | 1.25% |
| 2016 Q4 | 651.48 Million USD | 1.25% |
| 2016 Q3 | 643.43 Million USD | 1.25% |
| 2016 Q2 | 635.49 Million USD | 1.25% |
| 2015 Q2 | 659.96 Million USD | -5.39% |
| 2015 FY | 619.89 Million USD | -10.05% |
| 2015 Q4 | 619.89 Million USD | -0.65% |
| 2015 Q1 | 697.54 Million USD | 1.22% |
| 2015 Q3 | 623.93 Million USD | -5.46% |
| 2014 Q2 | 673.31 Million USD | 1.22% |
| 2014 Q4 | 689.11 Million USD | 1.15% |
| 2014 Q1 | 665.22 Million USD | 0.55% |
| 2014 Q3 | 681.31 Million USD | 1.19% |
| 2014 FY | 689.11 Million USD | 4.16% |
| 2013 Q4 | 661.56 Million USD | 253.52% |
| 2013 FY | 661.56 Million USD | 99.82% |
| 2013 Q1 | 337.51 Million USD | 1.94% |
| 2013 Q2 | 223.81 Million USD | -33.69% |
| 2013 Q3 | 187.13 Million USD | -16.39% |
| 2012 Q4 | 331.07 Million USD | -1.05% |
| 2012 FY | 331.07 Million USD | 4.72% |
| 2012 Q1 | 322.16 Million USD | 1.9% |
| 2012 Q2 | 328.31 Million USD | 1.91% |
| 2012 Q3 | 334.59 Million USD | 1.92% |
| 2011 Q2 | 304.53 Million USD | 1.88% |
| 2011 FY | 316.15 Million USD | 7.74% |
| 2011 Q4 | 316.15 Million USD | 1.89% |
| 2011 Q3 | 310.27 Million USD | 1.89% |
| 2011 Q1 | 298.91 Million USD | 1.87% |
| 2010 Q1 | 277.7 Million USD | -37.33% |
| 2010 FY | 293.43 Million USD | -33.78% |
| 2010 Q4 | 293.43 Million USD | 1.86% |
| 2010 Q3 | 288.06 Million USD | 1.85% |
| 2010 Q2 | 282.82 Million USD | 1.85% |
| 2009 FY | 443.13 Million USD | 11.86% |
| 2009 Q1 | 398.67 Million USD | 0.63% |
| 2009 Q3 | 477.41 Million USD | 18.99% |
| 2009 Q2 | 401.22 Million USD | 0.64% |
| 2009 Q4 | 443.13 Million USD | -7.18% |
| 2008 Q4 | 396.16 Million USD | 0.63% |
| 2008 Q1 | 388.89 Million USD | 0.61% |
| 2008 Q2 | 391.27 Million USD | 0.61% |
| 2008 Q3 | 393.7 Million USD | 0.62% |
| 2008 FY | 396.16 Million USD | 2.49% |
| 2007 FY | 386.55 Million USD | 4.16% |
| 2007 Q1 | 373.19 Million USD | 0.56% |
| 2007 Q3 | 377.5 Million USD | 0.58% |
| 2007 Q4 | 386.55 Million USD | 2.4% |
| 2007 Q2 | 375.33 Million USD | 0.57% |
| 2006 Q3 | 460.73 Million USD | 32.14% |
| 2006 Q1 | 348.63 Million USD | 1.98% |
| 2006 Q4 | 371.1 Million USD | -19.45% |
| 2006 FY | 371.1 Million USD | 8.55% |
| 2006 Q2 | 348.67 Million USD | 0.01% |
| 2005 FY | 341.86 Million USD | -9.74% |
| 2005 Q1 | 378.68 Million USD | -0.02% |
| 2005 Q2 | 349.5 Million USD | -7.71% |
| 2005 Q3 | 341.91 Million USD | -2.17% |
| 2005 Q4 | 341.86 Million USD | -0.02% |
| 2004 FY | 378.76 Million USD | 125.74% |
| 2004 Q1 | 417.68 Million USD | 148.94% |
| 2004 Q2 | 417.57 Million USD | -0.02% |
| 2004 Q4 | 378.76 Million USD | -0.02% |
| 2004 Q3 | 378.84 Million USD | -9.28% |
| 2003 Q1 | 171.93 Million USD | -0.06% |
| 2003 FY | 167.78 Million USD | -2.47% |
| 2003 Q4 | 167.78 Million USD | -0.06% |
| 2003 Q3 | 167.89 Million USD | -2.29% |
| 2003 Q2 | 171.82 Million USD | -0.06% |
| 2002 Q4 | 172.03 Million USD | -0.06% |
| 2002 FY | 172.03 Million USD | -4.02% |
| 2002 Q1 | 179.13 Million USD | -0.06% |
| 2002 Q2 | 172.25 Million USD | -3.84% |
| 2002 Q3 | 172.14 Million USD | -0.06% |
| 2001 Q4 | 179.24 Million USD | -0.06% |
| 2001 FY | 179.24 Million USD | -4.56% |
| 2001 Q1 | 179.58 Million USD | -4.38% |
| 2001 Q2 | 179.46 Million USD | -0.06% |
| 2001 Q3 | 179.35 Million USD | -0.06% |
| 2000 Q2 | 203.29 Million USD | -0.06% |
| 2000 Q1 | 203.42 Million USD | 101611.5% |
| 2000 FY | 187.81 Million USD | 93807.0% |
| 2000 Q3 | 203.16 Million USD | -0.06% |
| 2000 Q4 | 187.81 Million USD | -7.56% |
| 1999 FY | 200 Thousand USD | -75.0% |
| 1999 Q1 | 500 Thousand USD | -37.5% |
| 1999 Q2 | 400 Thousand USD | -20.0% |
| 1999 Q3 | 200 Thousand USD | -50.0% |
| 1999 Q4 | 200 Thousand USD | 0.0% |
| 1998 Q4 | 800 Thousand USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | 800 Thousand USD | -33.33% |
| 1998 Q2 | - USD | -100.0% |
| 1998 Q1 | 600 Thousand USD | -50.0% |
| 1997 FY | 1.2 Million USD | 1100.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q4 | 1.2 Million USD | 1100.0% |
| 1996 Q4 | 100 Thousand USD | -50.0% |
| 1996 Q3 | 200 Thousand USD | 100.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| 1995 FY | 100 Thousand USD | -50.0% |
| 1995 Q2 | 200 Thousand USD | 0.0% |
| 1995 Q3 | 200 Thousand USD | 0.0% |
| 1995 Q4 | 100 Thousand USD | -50.0% |
| 1995 Q1 | 200 Thousand USD | 0.0% |
| 1994 FY | 200 Thousand USD | -75.0% |
| 1994 Q1 | 700 Thousand USD | -12.5% |
| 1994 Q2 | 1.2 Million USD | 71.43% |
| 1994 Q3 | 800 Thousand USD | -33.33% |
| 1994 Q4 | 200 Thousand USD | -75.0% |
| 1993 Q3 | 600 Thousand USD | 0.0% |
| 1993 Q4 | 800 Thousand USD | 33.33% |
| 1993 FY | 800 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -4.793% |
| Dynavax Technologies Corporation | 256.91 Million USD | 85.097% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 7.802% |
| Perrigo Company plc | 4.07 Billion USD | 99.06% |
| Illumina, Inc. | 2.26 Billion USD | 98.307% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.89% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3728.7% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.599% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.731% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 77.965% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.583% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -41.856% |
| Waters Corporation | 2.35 Billion USD | 98.375% |
| Biogen Inc. | 7.33 Billion USD | 99.478% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -0.48% |
| Evolus, Inc. | 126.54 Million USD | 69.745% |
| Adicet Bio, Inc. | 17.7 Million USD | -116.274% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 11.305% |
| bluebird bio, Inc. | 330.32 Million USD | 88.409% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 92.922% |
| FibroGen, Inc. | 170.45 Million USD | 77.538% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.6% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -83.33% |
| Homology Medicines, Inc. | 44.05 Million USD | 13.091% |
| Geron Corporation | 85.89 Million USD | 55.428% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 98.403% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 91.397% |
| Myriad Genetics, Inc. | 145 Million USD | 73.595% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -2938.651% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 66.807% |
| Zoetis Inc. | 6.8 Billion USD | 99.437% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -769.764% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 98.234% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 96.623% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 95.264% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -5.407% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 97.366% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 33.842% |
| Verastem, Inc. | 41.55 Million USD | 7.869% |
| Nektar Therapeutics | 230.4 Million USD | 83.382% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 79.457% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1145.511% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 97.259% |
| OPKO Health, Inc. | 326.56 Million USD | 88.276% |
| Exelixis, Inc. | 189.94 Million USD | 79.843% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 91.063% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -25255.629% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 72.338% |
| Imunon, Inc. | 1.13 Million USD | -3260.593% |
| Blueprint Medicines Corporation | 774.12 Million USD | 95.054% |
| Insmed Incorporated | 1.2 Billion USD | 96.82% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.446% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 32.816% |
| TG Therapeutics, Inc. | 110.79 Million USD | 65.443% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 95.637% |